Agios Pharmaceuticals (AGIO) Accumulated Expenses (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Accumulated Expenses data on file, last reported at $34.6 million in Q2 2026.

• Quarterly Accumulated Expenses fell 1.82% year-over-year to $34.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $34.6 million (down 1.82% YoY) and the FY2025 annual result came in at $45.5 million, down 2.99% from the prior year.
• Accumulated Expenses rose to $34.6 million in Q2 2026, from $26.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $46.9 million in Q4 2024 to a low of $19.7 million in Q1 2022.
• A 5-year average of $32.0 million and a median of $30.4 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses decreased 21.28% — and 2023, when it jumped 42.23%.
• Tracing AGIO's Accumulated Expenses over 5 years: stood at $30.4 million in 2022, then jumped by 42.23% to $43.2 million in 2023, then gained by 8.56% to $46.9 million in 2024, then dropped by 2.99% to $45.5 million in 2025, then slipped by 23.78% to $34.6 million in 2026.
• The last three Accumulated Expenses figures came in at $34.6 million (Q2 2026), $26.3 million (Q1 2026), and $45.5 million (Q4 2025), per Business Quant data.